In an in vivo model of breast cancer brain metastases (BCBMs), intratumoral administration of oncolytic herpes simplex virus (oHSV) and EGFR-CAR-NK-92 cells resulted in improved killing of cancer cells and longer survival, when compared to monotherapy (96). This evidence concerns the gene EGFR and breast carcinoma.